Vedolizumab
- Generic Name
- Vedolizumab
- Brand Names
- Entyvio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 943609-66-3
- Unique Ingredient Identifier
- 9RV78Q2002
- Background
Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative colitis or Crohn's disease. α4β7 integrin facilitates the interaction between lymphocytes and gut endothelial cells through the α4β7 integrin-MAdCAM1 intera...
- Indication
Vedolizumab is indicated for adult patients with moderately to severely active Ulcerative Colitis or Crohn’s disease.
- Associated Conditions
- Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath